63 results for Patent

  • Novel food product and method of use

    Johnson, PS; Lee, S; Altalhi, ASD (2016-03-03)

    Patent
    Massey University

    The invention includes a composition when used for the subsequent preparation of an egg white foam, characterised in that the composition includes an amount of egg white material and at least one thickener. The amount of thickener(s) is at least about 2.0%w/w in the composition and the composition has been heat treated at or above about 40°Cprior to preparing the egg white foam. The invention also encompasses method of use, novel food products, cooked or uncooked, and methods of manufacture.

    View record details
  • GPE Analogues and Peptidomimetics

    Abood, NA; Brimble, MA (2003)

    Patent
    The University of Auckland Library

    This invention relates to analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic and anti-necrotic, to methods of making them, to pharmaceutical compositions containing them, and to their use.

    View record details
  • Neuroprotective Bicyclic Compounds and Methods for their Use

    Brimble, MA; Sieg, F; Guan, J (2007)

    Patent
    The University of Auckland Library

    Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

    View record details
  • Compositions and Methods for Regulating Plant Gene Expression

    Espley,, RV; Hellens,, RP; Allan,, AC; Chagné,, D (2008)

    Patent
    The University of Auckland Library

    The invention provides a method for producing a chimeric promoter polynucleotide capable of controlling transcription of an operably linked polynucleotide in a plant cell or plant, wherein the method comprises combining: a) at least one sequence motif comprising a sequence with at least 70% identity to SEQ ID NO:1, 11 or 12, and b) another polynucleotide sequence. The invention also provides chimeric promoters polynucleotides comprising the sequences defined in a) and b). The invention also provides constructs, vectors, host cells, plant cells and plants comprising the chimeric promoter polynucleotides of the invention. The invention also provided methods for modifying gene expression and phenotype of plant cells and plants by transforming the plant cells and plants with the chimeric promoter polynucleotides of the invention.

    View record details
  • Transcription factors

    Bloksberg, LN; Bryant, C; Connett, MB; Emerson, SJ; Forster, RLS; Frost, J; Gause, K; Grigor, M; Havukkala, I; Higgins, C; Lasham, Annette; Lund, ST; Magusin, A; Phillips, J; Puthigae, S; Rottmann, WH; Veerakone, S; Westwood, C; Wood, M (2012)

    Patent
    The University of Auckland Library

    The invention provides polynucleotide sequences isolated from plants encoding transcription factors. Polypeptides encoded by the polynucleotides are also provided. Products and methods of use are disclosed.

    View record details
  • Cascaded Raman Laser

    Martinelli, C; Leplingard, F; Sylvestre, T; Vanholsbeeck, Frederique; Emplit, P (2006-02-07)

    Patent
    The University of Auckland Library

    A cascaded Raman laser (10) has a pump radiation source (12) emitting at a pump wavelength λp, an input section (14) and an output section (16) made of an optical medium. Each section (14, 16) comprises wavelength selectors (141, 142, . . . , 145 and 161, 162, . . . , 165) for wavelengths λ1, λ2, . . . , λn−k, where n≧3, λp< . . . <λn and λn−k+1, λn−k+2, . . . , λn being k≧1 emitting wavelengths of the laser (10). The laser further comprises an intracavity section (18) that is made of a non-linear optical medium, has a zero-dispersion wavelength λ0 and is disposed between the input (14) and the output (16) section. The wavelengths λ1, λ2, . . . , λn−k of the wavelength selectors (141, 142, . . . , 145 and 161, 162, . . . , 165) and the zero-dispersion wavelength λ0 of the intracavity section (18) are chosen such that energy is transferred between different wavelengths by multi-wave mixing.

    View record details
  • Kinase inhibitors, prodrug forms thereof and their use in therapy.

    Smaill,, JB; Patterson, AV; Lu, G-L; Lee, Ho; Ashoorzadeh, A; Anderson, RF; Wilson, WR; Denny, WA; Hsu, A; Maroz, A; Jamieson, SMF; Mowday, AM; Carlin, KM (2011-03-10)

    Patent
    The University of Auckland Library

    The present invention relates to pyrido[3,4-d]pyrimidine compounds of formula (I) suitable as kinase inhibitors, kinase inhibitors in prodrug form, their use in compositions and medicaments which are suitable for the treatment of diseases related to kinase activity such as cancers.

    View record details
  • Oral formulations of Glycyl-2-Methylprolyl-Glutamate.

    Wen, Jingyuan; Thomas, G; Bickerdike, MJ (2009)

    Patent
    The University of Auckland Library

    Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.

    View record details
  • Marker assisted selection of a mammalian subject for desired phenotype

    Davis, S; Lehnert, K; Berry, SDK; Snell, Russell; Beattie, EM (2011)

    Patent
    The University of Auckland Library

    The present invention provides methods of genotyping mammalian subjects for desired lactoferrin phenotypes by determining the lactoferrin genotype of the subject. The invention particularly provides methods wherein the presence or absence of the T allele or the C allele at the 30126 T/C polymorphism, of the A allele or the G allele at the 7447 A/G polymorphism, or of the C allele or the G allele at the -7 G/C polymorphism in the bovine Lf gene, is associated with increased or decreased lactoferrin production or secretion, including increased or decreased milk or colostrum Lf content.

    View record details
  • Dielectric elastomer self-sensing using plane approximation

    O'Brien, BM; Gisby, TA; Anderson, IA (2011)

    Patent
    The University of Auckland Library

    The present invention provides a method for obtaining feedback parameters related to the state of a dielectric elastomer (DE). The method comprises introducing a small-scale oscillation to the voltage difference between electrodes of the DE, monitoring or repeatedly measuring several measurable electrical characteristics of the DE, deriving other relevant data from the measurements, deriving an equation for a plane of best fit through the relevant data when defined as orthogonal axes, and deriving the feedback parameters from coefficients of the plane equation. The method thus provides important feedback regarding the capacitance, leakage current and/or electrode resistance of the DE. Also disclosed are a computer program and a system adapted to perform the method.

    View record details
  • Adrenocorticotropic hormone analogs and related methods

    Brennan, MB; Costa, Jessica; Dores, RM; Hochgeschwender, U; Haskell-Luevano, C (2007)

    Patent
    The University of Auckland Library

    ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.

    View record details
  • System and method for tracking facial muscle and eye motion for computer graphics animation

    Sagar, Mark; Scott, R (2009)

    Patent
    The University of Auckland Library

    A motion tracking system enables faithful capture of subtle facial and eye motion using a surface electromyography (EMG) detection method to detect muscle movements and an electrooculogram (EOG) detection method to detect eye movements. An embodiment of the motion tracking animation system comprises a plurality of pairs of EOG electrodes adapted to be affixed to the skin surface of the performer at locations adjacent to the performer's eyes. The EOG data comprises electrical signals corresponding to eye movements of a performer during a performance. Programming instructions further provide processing of the EOG data and mapping of processed EOG data onto an animated character. As a result, the animated character will exhibit he same muscle and eye movements as the performer.

    View record details
  • Murine endometriosis modelled by K-ras activation of menstruating endometrium

    Charnock-Jones, D; Print, Cristin; Cheng, C (2009)

    Patent
    The University of Auckland Library

    View record details
  • Interactive gaming system

    Searchfield, GD; Kobayashi, Kei; Wise, KJ (2012)

    Patent
    The University of Auckland Library

    The present invention relates to an interactive gaming system for auditory training rehabilitation relating to tinnitus.

    View record details
  • Neuroprotective Bicyclic Compounds and Methods for their Use

    Brimble, Margaret; Guan, Jian; Sieg, Frank (2005-03-17)

    Patent
    The University of Auckland Library

    Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

    View record details
  • Model Assisted Planning of Medical Imaging

    Cowan, BR; O'donnell, T; Young, Alistair (2005-01-13)

    Patent
    The University of Auckland Library

    A method (600) and system (700) for medical image acquisition are provided, where the method (600) includes acquiring an image of the region of interest (610), acquiring a model for a region of interest (620), and fitting the model to the image (630); the system (700) includes a modeling unit for modeling a region of interest (770); an acquisition unit in signal communication with the modeling unit for acquiring an image of the region of interest (732); and a fitting unit in signal communication with the acquisition unit for fitting the model to the image (780).

    View record details
  • Effects of Glycyl-2-methylprolylglutamate on Neurodegeneration

    Gluckman, Peter; Thomas, GB; Guan, J; Dragunow, M; Anand, Ashmit; Kerlero de Rosbo, N; Sieg, F; Brimble, Margaret (2007-12-27)

    Patent
    The University of Auckland Library

    This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.

    View record details
  • Neural Regeneration Peptides and Methods for their Use

    Sieg, F; Brimble, Margaret; Muir, Victoria (2010-05-27)

    Patent
    The University of Auckland Library

    Embodiments of this invention include novel peptides that can promote survival of neurons and other cell types. Other embodiments of this invention include the methods for the use of peptides to promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation, neuronal survival and/or trophoblast proliferation, trophoblast migration and trophoblase survival. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly or indirectly via a replicable vehicle. NRP compounds can be formulated into pharmaceutically acceptable dosage forms for therapeutic use. Kits containing pre-determined doses of an NRP can be used to conveniently store, prepare and administer an NRP to a subject in need thereof.

    View record details
  • Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate

    Gluckman, Peter; Brimble, Margaret; Wilson, D; Tortella, FC; Williams, AJ; Xi-Chun, ML; Hartings, JA; Gryder, D (2010-05-11)

    Patent
    The University of Auckland Library

    Aspects of this invention include the use of G-2MePE to treat patients with brain injury characterized by non-convulsive seizures. G-2MePE is useful in treating brain injuries caused by traumatic brain injury, stroke, hypoxia/ischemia and toxic injury.

    View record details
  • Directly photodefinable polymer compositions and methods thereof

    Elce, E; Bell, A; Knapp, B; Ng, H; Rhodes, LF; Shick, R; Zhang, W; Dimenna, W; Jayaraman, S; Jin, Jianyong; Puthenkovilakom, RR; Ravikiran, R; Wu, X; Takeuchi, E (2011)

    Patent
    The University of Auckland Library

    A polymer includes a first type of repeat unit represented by Formula I, where X is selected from -CH2-, -CH2-CH2-, or -O-; m is an integer from 0 to about 5; and where for the first type of repeat unit one of R1, R2, R3, and R4 is one of a maleimide containing group and for the second type of repeat unit one of R1, R2, R3, and R4 is a hindered aromatic group, a C8 or greater alkyl group, a C4 or greater halohydrocarbyl or perhalocarbyl group, a C7 or greater aralkyl group, or a heteroatom hydrocarbyl or halohydrocarbyl group.

    View record details